Eli Lilly's orforglipron and Pfizer's daily acting danuglipron represent the latest oral non-peptide GLP-1 agonists, striving for parity in efficacy with the injectables, with the advantage of being more readily manufactured
High-fat foods sit in the stomach even longer than standard foods
The time is now
In addition to their impact on appetite and consummatory behaviors [207, 208], several mechanisms have been proposed to mediate GLP-1RAs effects on alcohol intake, including interactions with reward-related pathways [209,210,211,212], stress [213,214,215], cognition and neuroprotection [216,217,218], pain and aversion [113, 219, 220], and inflammation [221,222,223]